Tarsus Pharmaceuticals, Inc.
TARS
$69.20
$0.320.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -166.27% | 16.79% | 33.47% | 38.13% | 19.03% |
| Total Depreciation and Amortization | 128.83% | -1.35% | -3.70% | 1.55% | -1.52% |
| Total Amortization of Deferred Charges | 4.40% | 1.92% | 2.63% | 4.11% | 5.04% |
| Total Other Non-Cash Items | -10.85% | -17.25% | 24.10% | 62.50% | 16.07% |
| Change in Net Operating Assets | 332.83% | -317.13% | -29.77% | 218.18% | -756.28% |
| Cash from Operations | 348.35% | -227.53% | 5.88% | 162.13% | -42.30% |
| Capital Expenditure | 30.06% | 8.49% | -232.88% | -90.81% | -69.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 179.53% | -194.81% | 2,063.71% | 94.41% | -47.60% |
| Cash from Investing | 164.68% | -218.85% | 1,138.88% | 90.83% | -47.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 174.25% | -47.92% | -9.76% | 31.25% | -98.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 174.25% | -47.92% | -9.76% | 31.25% | -98.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 224.87% | -215.64% | 341.13% | 120.31% | -197.74% |